LT4982B - N-heterocikliniai dariniai kaip nos inhibitoriai - Google Patents

N-heterocikliniai dariniai kaip nos inhibitoriai Download PDF

Info

Publication number: LT4982B
Authority: LT; Lithuania
Prior art keywords: amino; imidazol; methylpyrimidin; acetamide; ethyl
Prior art date: 1999-08-26

Application number

LT2002028A

Other languages

English (en)

Lithuanian (lt)

Other versions

LT2002028A (en

Inventor

Damian O. Arnaiz

John J. Baldwin

David D. Davey

James J. Devlin

Roland Ellwood Dolle Iii

Bin Ye

Gary B. Phillips

Gonghua Pan

John Parkinson

Kirk Mcmillan

Michael H.J. Ohlmeyer

Michael M. Morrissey

Shawn David Erickson

Vidyadhar Madhav Paradkar

Zuchun Zhao

Original Assignee

Berlex Laboratories,Inc.

Pharmacopeia,Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-08-26

Filing date

2002-03-15

Publication date

2003-01-27

2002-03-15 Application filed by Berlex Laboratories,Inc., Pharmacopeia,Inc. filed Critical Berlex Laboratories,Inc.

2002-09-25 Publication of LT2002028A publication Critical patent/LT2002028A/xx

2003-01-27 Publication of LT4982B publication Critical patent/LT4982B/lt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Psychology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Obesity (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

LT2002028A 1999-08-26 2002-03-15 N-heterocikliniai dariniai kaip nos inhibitoriai LT4982B (lt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US09/383,813 US6432947B1 (en)	1997-02-19	1999-08-26	N-heterocyclic derivatives as NOS inhibitors

Publications (2)

Publication Number	Publication Date
LT2002028A LT2002028A (en)	2002-09-25
LT4982B true LT4982B (lt)	2003-01-27

Family

ID=23514822

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LT2002028A LT4982B (lt)	1999-08-26	2002-03-15	N-heterocikliniai dariniai kaip nos inhibitoriai

Country Status (34)

Country	Link
US (11)	US6432947B1 (et)
EP (1)	EP1206467B1 (et)
JP (1)	JP4739625B2 (et)
KR (1)	KR100708783B1 (et)
CN (1)	CN1206228C (et)
AT (1)	ATE256681T1 (et)
AU (1)	AU769405B2 (et)
BG (1)	BG65804B1 (et)
BR (1)	BR0014144A (et)
CA (1)	CA2376355C (et)
CZ (1)	CZ2002642A3 (et)
DE (1)	DE60007329T2 (et)
DK (1)	DK1206467T3 (et)
EE (1)	EE05199B1 (et)
ES (1)	ES2213599T3 (et)
HK (1)	HK1043594A1 (et)
HR (1)	HRP20020175B1 (et)
HU (1)	HUP0202450A3 (et)
IL (2)	IL148313A0 (et)
LT (1)	LT4982B (et)
LV (1)	LV12887B (et)
MX (1)	MXPA02002022A (et)
NO (1)	NO323886B1 (et)
NZ (1)	NZ517411A (et)
PL (1)	PL353539A1 (et)
PT (1)	PT1206467E (et)
RO (1)	RO122202B1 (et)
RS (1)	RS50378B (et)
RU (1)	RU2277094C2 (et)
SI (1)	SI20818B (et)
SK (1)	SK2622002A3 (et)
UA (1)	UA72930C2 (et)
WO (1)	WO2001014371A1 (et)
ZA (1)	ZA200201485B (et)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6432947B1 (en) *	1997-02-19	2002-08-13	Berlex Laboratories, Inc.	N-heterocyclic derivatives as NOS inhibitors
HRP990246A2 (en) *	1998-08-07	2000-06-30	Du Pont Pharm Co	Succinoylamino benzodiazepines as inhibitors of a beta protein production
NZ509241A (en)	1998-08-07	2003-08-29	Du Pont Pharm Co	Succinoylamino lactams as inhibitors of alpha-beta protein production
DE60005355T2 (de) *	1999-07-15	2004-07-01	Pharmacopeia, Inc.	Bradikinin b1 rezeptor antagonisten
GB2361473C (en) *	2000-03-08	2005-06-28	Microgenics Corp	Ecstasy-class analogs and use of same in detection of ecstasy-class compounds
CA2404023A1 (en) *	2000-04-03	2001-10-11	Richard E. Olson	Cyclic lactams as inhibitors of a.beta. protein production
US20030055249A1 (en) *	2001-07-17	2003-03-20	Fick David B.	Synthesis and methods of use of pyrimidine analogues and derivatives
US7778711B2 (en) *	2001-08-31	2010-08-17	Bio Control Medical (B.C.M.) Ltd.	Reduction of heart rate variability by parasympathetic stimulation
US7885709B2 (en) *	2001-08-31	2011-02-08	Bio Control Medical (B.C.M.) Ltd.	Nerve stimulation for treating disorders
US7904176B2 (en)	2006-09-07	2011-03-08	Bio Control Medical (B.C.M.) Ltd.	Techniques for reducing pain associated with nerve stimulation
US8571653B2 (en) *	2001-08-31	2013-10-29	Bio Control Medical (B.C.M.) Ltd.	Nerve stimulation techniques
EP1795192A3 (en) *	2002-04-30	2008-05-07	Bayer Schering Pharma Aktiengesellschaft	1-(Pyridazin-3-yl)-imidazole derivatives as inhibitors of nitric oxide synthase (NOS)
US6982259B2 (en) *	2002-04-30	2006-01-03	Schering Aktiengesellschaft	N-heterocyclic derivatives as NOS inhibitors
AU2003260033A1 (en) *	2002-08-29	2004-03-19	Schering Aktiengesellschaft	Methods of treating acute respiratory distress syndrome
EP1556373A1 (en) *	2002-10-18	2005-07-27	Pfizer Products Inc.	Cannabinoid receptor ligands and uses thereof
AU2005214319B2 (en) *	2004-02-12	2009-02-19	Merck Sharp & Dohme Corp.	Amino heterocyclic modulators of chemokine receptor activity
EP1568698A1 (en) *	2004-02-27	2005-08-31	Aventis Pharma Deutschland GmbH	Pyrrole-derivatives as factor Xa inhibitors
MY144044A (en) *	2004-06-10	2011-07-29	Irm Llc	Compounds and compositions as protein kinase inhibitors
KR100935273B1 (ko) *	2004-06-10	2010-01-06	아이알엠 엘엘씨	단백질 키나제 억제제 화합물 및 조성물
CA2581454A1 (en) *	2004-09-23	2006-03-30	Reddy Us Therapeutics, Inc.	Novel pyrimidine compounds, process for their preparation and compositions containing them
MY179032A (en) *	2004-10-25	2020-10-26	Cancer Research Tech Ltd	Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
UY29177A1 (es) *	2004-10-25	2006-05-31	Astex Therapeutics Ltd	Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
KR20070086188A (ko) *	2004-11-17	2007-08-27	미카나 테라퓨틱스, 인크.	키나제 억제제
US20070123572A1 (en) *	2005-11-28	2007-05-31	Kalypsys, Inc.	Novel method of preparation of 5-chloro-3-imidazol-1-yl-[1,2,4]thiadiazole and (3-imidazol-1-yl-[1,2,4]thiadiazol-5yl)-dialkyl-amines
EP1817030A2 (en) *	2004-12-01	2007-08-15	Kalypsys, Inc.	Inducible nitric oxide synthase dimerization inhibitors
KR101155335B1 (ko) *	2005-01-07	2012-06-11	엘지전자 주식회사	이동통신 단말기의 멀티미디어 메시지 동작방법
US7884109B2 (en) *	2005-04-05	2011-02-08	Wyeth Llc	Purine and imidazopyridine derivatives for immunosuppression
RU2007140903A (ru) *	2005-04-05	2009-05-20	Фармакопия, Инк. (Us)	Производные пурина и имидазопиридина для иммуносупрессии
US7812025B2 (en) *	2005-08-12	2010-10-12	Takeda Pharmaceutical Company Limited	Brain/neuronal cell-protecting agent and therapeutic agent for sleep disorder
ES2535854T3 (es) *	2005-09-30	2015-05-18	Miikana Therapeutics, Inc.	Compuestos de pirazol sustituidos
EP1954694A1 (en) *	2005-11-28	2008-08-13	Kalypsys, Inc.	Imidazole derivatives as nitric oxide synthase dimerisation inhibitor
US7989459B2 (en) *	2006-02-17	2011-08-02	Pharmacopeia, Llc	Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
US20090281075A1 (en) *	2006-02-17	2009-11-12	Pharmacopeia, Inc.	Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
US8017612B2 (en) *	2006-04-18	2011-09-13	Japan Tobacco Inc.	Piperazine compound and use thereof as a HCV polymerase inhibitor
EP3421471B1 (en) *	2006-04-25	2021-05-26	Astex Therapeutics Limited	Purine and deazapurine derivatives as pharmaceutical compounds
EP2013206A1 (en) *	2006-04-25	2009-01-14	Astex Therapeutics Limited	Pharmaceutical compounds
EP3146982B1 (en)	2006-10-03	2019-08-21	Genzyme Corporation	Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders
WO2008043019A1 (en) *	2006-10-04	2008-04-10	Pharmacopeia, Inc	8-substituted 2-(benzimidazolyl) purine derivatives for immunosuppression
US7902187B2 (en) *	2006-10-04	2011-03-08	Wyeth Llc	6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
AR063142A1 (es) *	2006-10-04	2008-12-30	Pharmacopeia Inc	Derivados de 2-(bencimidazolil) purina y purinonas 6-sustituidas utiles como inmunosupresores,y composiciones farmaceuticas que los contienen.
US20080119496A1 (en) *	2006-11-16	2008-05-22	Pharmacopeia Drug Discovery, Inc.	7-Substituted Purine Derivatives for Immunosuppression
EP1939181A1 (en) *	2006-12-27	2008-07-02	sanofi-aventis	Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase
AU2008262291A1 (en) *	2007-06-11	2008-12-18	Miikana Therapeutics, Inc.	Substituted pyrazole compounds
ES2522365T3 (es)	2007-10-11	2014-11-14	Astrazeneca Ab	Derivados de pirrolo [2,3-D] pirimidina como inhibidores de proteína quinasas B
EP2240025A4 (en) *	2008-01-30	2012-03-28	Glaxosmithkline Llc	NEW SEE INHIBITORS AND THEIR USE
US20100324076A1 (en) *	2008-01-30	2010-12-23	Joseph Paul Marino	Novel sEH Inhibitors and their Use
US20100311776A1 (en) *	2008-01-30	2010-12-09	Smithkline Beecham Corporation	Novel sEH Inhibitors and their Use
US20110053907A1 (en) *	2008-03-27	2011-03-03	Auckland Uniservices Limited	Substituted pyrimidines and triazines and their use in cancer therapy
GB0908394D0 (en)	2009-05-15	2009-06-24	Univ Leuven Kath	Novel viral replication inhibitors
GB0913636D0 (en)	2009-08-05	2009-09-16	Univ Leuven Kath	Novel viral replication inhibitors
BR112012006130A2 (pt)	2009-09-18	2016-06-28	Volvo Lastvagnar Ab	console para atamento para um chassi de veículo e veículo compreendendo um console de transporte de suspensão.
EP2640705A2 (en)	2010-11-15	2013-09-25	Katholieke Universiteit Leuven	Novel antiviral compounds
CN102617503B (zh) *	2011-03-03	2014-05-07	上海常丰生物医药科技有限公司	(s)-3-吗啉基羧酸的合成方法
US9402847B2 (en)	2011-04-01	2016-08-02	Astrazeneca Ab	Combinations comprising (S)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide
DK2785349T4 (da)	2011-11-30	2023-01-09	Astrazeneca Ab	Kombinationsbehandling af cancer
AU2013204533B2 (en)	2012-04-17	2017-02-02	Astrazeneca Ab	Crystalline forms
EP3166938A4 (en) *	2014-07-11	2018-01-17	Northwestern University	2-imidazolyl-pyrimidine scaffolds as potent and selective inhibitors of neuronal nitric oxide synthase
GB201512635D0 (en)	2015-07-17	2015-08-26	Ucl Business Plc	Uses of therapeutic compounds
US10407446B2 (en)	2016-12-20	2019-09-10	Astrazeneca Ab	Amino-triazolopyridine compounds and their use in treating cancer
CN107115334A (zh) *	2017-03-04	2017-09-01	王宏	一种治疗免疫性流产的药物组合物
AU2019237507B2 (en)	2018-03-23	2025-04-03	Carmot Therapeutics, Inc.	Modulators of G-protein coupled receptors
EP3628669A1 (en)	2018-09-28	2020-04-01	GenKyoTex Suisse SA	Novel compounds as nadph oxidase inhibitors
MX2023013492A (es)	2021-05-13	2024-02-29	Carmot Therapeutics Inc	Moduladores de los receptores acoplados a proteinas g.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6339875A (ja)	1986-08-05	1988-02-20	Nissin Food Prod Co Ltd	ピリミジン誘導体
DE4118720A1 (de)	1991-06-07	1992-12-10	Bayer Ag	Substituierte imidazolinylpyrimidine
TW212798B (et) *	1991-11-25	1993-09-11	Takeda Pharm Industry Co Ltd
AU665238B2 (en) *	1992-02-28	1995-12-21	Zenyaku Kogyo Kabushiki Kaisha	S-triazine derivative and remedy for estrogen-dependent diseases containing the same as active ingredient
TW279864B (et) *	1993-02-19	1996-07-01	Janssen Pharmaceutica Nv
US5593992A (en)	1993-07-16	1997-01-14	Smithkline Beecham Corporation	Compounds
DE69408750T2 (de)	1993-08-26	1998-07-23	Ono Pharmaceutical Co	4-Aminopyrimidin Derivate
US5426110A (en)	1993-10-06	1995-06-20	Eli Lilly And Company	Pyrimidinyl-glutamic acid derivatives
US5629322A (en)	1994-11-15	1997-05-13	Merck & Co., Inc.	Cyclic amidine analogs as inhibitors of nitric oxide synthase
AU4149696A (en)	1994-11-15	1996-06-06	Merck & Co., Inc.	Substituted heterocycles as inhibitors of nitric oxide synthase
BR9611157A (pt) *	1995-11-01	1999-03-30	Novartis Ag	Derivados de purina e processos para sua preparação
ZA977427B (en)	1996-09-04	1998-03-02	Dainippon Pharmaceutical Co	2,4-disubstituted pyrimidine derivative, process for preparing the same, and a pharmaceutical composition containing the same.
WO1998037079A1 (en) *	1997-02-19	1998-08-27	Berlex Laboratories, Inc.	N-heterocyclic derivatives as nos inhibitors
US6432947B1 (en) *	1997-02-19	2002-08-13	Berlex Laboratories, Inc.	N-heterocyclic derivatives as NOS inhibitors
EP0970072A1 (en) *	1997-03-11	2000-01-12	E.I. Dupont De Nemours And Company	Heteroaryl azole herbicides
US6525051B2 (en)	2000-03-27	2003-02-25	Schering Aktiengesellschaft	N-heterocyclic derivatives as NOS inhibitors

1999
- 1999-08-26 US US09/383,813 patent/US6432947B1/en not_active Expired - Fee Related
2000
- 2000-08-24 AU AU70671/00A patent/AU769405B2/en not_active Ceased
- 2000-08-24 PL PL00353539A patent/PL353539A1/xx not_active Application Discontinuation
- 2000-08-24 MX MXPA02002022A patent/MXPA02002022A/es active IP Right Grant
- 2000-08-24 BR BR0014144-5A patent/BR0014144A/pt not_active Application Discontinuation
- 2000-08-24 RO ROA200200205A patent/RO122202B1/ro unknown
- 2000-08-24 NZ NZ517411A patent/NZ517411A/en unknown
- 2000-08-24 EP EP00959333A patent/EP1206467B1/en not_active Expired - Lifetime
- 2000-08-24 PT PT00959333T patent/PT1206467E/pt unknown
- 2000-08-24 RU RU2002107203/04A patent/RU2277094C2/ru not_active IP Right Cessation
- 2000-08-24 IL IL14831300A patent/IL148313A0/xx active IP Right Grant
- 2000-08-24 CN CNB008146691A patent/CN1206228C/zh not_active Expired - Fee Related
- 2000-08-24 CZ CZ2002642A patent/CZ2002642A3/cs unknown
- 2000-08-24 CA CA002376355A patent/CA2376355C/en not_active Expired - Fee Related
- 2000-08-24 HR HR20020175A patent/HRP20020175B1/xx not_active IP Right Cessation
- 2000-08-24 AT AT00959333T patent/ATE256681T1/de not_active IP Right Cessation
- 2000-08-24 WO PCT/US2000/023173 patent/WO2001014371A1/en not_active Ceased
- 2000-08-24 DK DK00959333T patent/DK1206467T3/da active
- 2000-08-24 SI SI200020040A patent/SI20818B/sl not_active IP Right Cessation
- 2000-08-24 DE DE60007329T patent/DE60007329T2/de not_active Expired - Lifetime
- 2000-08-24 EE EEP200200091A patent/EE05199B1/et not_active IP Right Cessation
- 2000-08-24 HU HU0202450A patent/HUP0202450A3/hu unknown
- 2000-08-24 RS YUP-120/02A patent/RS50378B/sr unknown
- 2000-08-24 HK HK02105317.3A patent/HK1043594A1/zh unknown
- 2000-08-24 SK SK262-2002A patent/SK2622002A3/sk unknown
- 2000-08-24 UA UA2002032401A patent/UA72930C2/uk unknown
- 2000-08-24 JP JP2001518702A patent/JP4739625B2/ja not_active Expired - Fee Related
- 2000-08-24 ES ES00959333T patent/ES2213599T3/es not_active Expired - Lifetime
- 2000-08-24 KR KR1020027002407A patent/KR100708783B1/ko not_active Expired - Fee Related
2002
- 2002-02-21 ZA ZA200201485A patent/ZA200201485B/en unknown
- 2002-02-21 IL IL148313A patent/IL148313A/en not_active IP Right Cessation
- 2002-02-26 NO NO20020925A patent/NO323886B1/no not_active IP Right Cessation
- 2002-02-26 BG BG106440A patent/BG65804B1/bg unknown
- 2002-03-15 LT LT2002028A patent/LT4982B/lt not_active IP Right Cessation
- 2002-03-26 LV LVP-02-50A patent/LV12887B/en unknown
- 2002-04-12 US US10/122,047 patent/US6887865B2/en not_active Expired - Fee Related
- 2002-04-12 US US10/122,072 patent/US6841674B2/en not_active Expired - Fee Related
- 2002-04-12 US US10/121,659 patent/US6864263B2/en not_active Expired - Fee Related
- 2002-04-12 US US10/121,886 patent/US6841673B2/en not_active Expired - Fee Related
- 2002-04-12 US US10/122,006 patent/US6864368B2/en not_active Expired - Fee Related
- 2002-04-12 US US10/121,379 patent/US6747031B2/en not_active Expired - Fee Related
- 2002-04-12 US US10/121,808 patent/US6670473B2/en not_active Expired - Fee Related
- 2002-04-12 US US10/121,682 patent/US20030073669A1/en not_active Abandoned
- 2002-04-12 US US10/121,212 patent/US6849739B2/en not_active Expired - Fee Related
- 2002-04-12 US US10/121,758 patent/US6846829B2/en not_active Expired - Fee Related

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
AOYAMA Y ET AL.: "Inhibition by a novel azole antifungal agent with a geranyl group on lanosterol 14 alpha-demethylase of yeast", BIOCHEM PHARMACOL., 1992, pages 1701 - 1705
CHABIN RM ET AL.: "Active-site structure analysis of recombinant human inducible nitric oxide synthase using imidazole", BIOCHEMISTRY, 1996, pages 9567 - 9575
CHWALISZ, K. ; BUHIMSCHI, I. ; GARFIELD, R. E: "Role of nitric oxide in obstetrics", PERINATAL AND NEONATAL MEDICINE, 1996, pages 292 - 329
D. CORY ADAMSON ET AL.: "Immunologic NO Synthase: Elevation in Severe AIDS Dementia and Induction by HIV-1 gp41", SCIENCE, 1996, pages 1917 - 1921
H. MICHAEL BELMONT MD ET AL.: "Increased nitric oxide production accompanied by the up-regulation of inducible nitric oxide synthase in vascular endothelium from patients with systemic lupus erythematosus", ARTHRITIS AND RHEUMATISM, 1997, pages 1810 - 1816
HUNOT S ET AL.: "Nitric oxide synthase and neuronal vulnerability in Parkinsons disease", NEUROSCIENCE. 1996 MAY;72(2):355-63. NITRIC OXI, 1996, pages 355 - 3563
J B WEINBERG ET AL.: "The role of nitric oxide in the pathogenesis of spontaneous murine autoimmune disease: increased nitric oxide production and nitric oxide synthase expression in MRL-lpr/lpr mice, and reduction of spontaneous glomerulonephritis and arthritis by orally admi", J. EXP. MED, 1994, pages 651 - 660
J. NEUROSCI: "Delayed Reduction of Ischemic Brain Injury and Neurological Deficits in Mice Lacking the Inducible Nitric Oxide Synthase Gene", J. NEUROSCI., 1997, pages 9157 - 9164, XP000867073
MAURICE M ET AL.: "Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture", FASEB J., 1992, pages 752 - 758, XP002715403
PARKINSON JF, MITROVIC B, MERRILL JE.: "The role of nitric oxide in multiple sclerosis", J MOL MED (BERL), 1997, pages 174 - 186
SMITH, M.A. ET AL.: "Widespread peroxynitrite-mediated damage in Alzheimers disease", J. NEUROSCI., 1997, pages 2653 - 2657, XP002379310
WALLACE MN: "Nitric oxide synthase in reactive astrocytes adjacent to beta-amyloid plaques", EXP NEUROL., 1997, pages 266 - 272

Also Published As

Publication number	Publication date
YU12002A (sh)	2005-03-15
BG65804B1 (bg)	2009-12-31
KR100708783B1 (ko)	2007-04-19
NO20020925L (no)	2002-04-16
US6864368B2 (en)	2005-03-08
CA2376355A1 (en)	2001-03-01
US6841673B2 (en)	2005-01-11
EE05199B1 (et)	2009-08-17
EE200200091A (et)	2003-04-15
SI20818B (sl)	2009-04-30
US6670473B2 (en)	2003-12-30
US20020165203A1 (en)	2002-11-07
JP4739625B2 (ja)	2011-08-03
DK1206467T3 (da)	2004-04-26
US20030027794A1 (en)	2003-02-06
ES2213599T3 (es)	2004-09-01
CN1382136A (zh)	2002-11-27
US20030092678A1 (en)	2003-05-15
ATE256681T1 (de)	2004-01-15
AU7067100A (en)	2001-03-19
SK2622002A3 (en)	2002-09-10
US6864263B2 (en)	2005-03-08
RO122202B1 (ro)	2009-02-27
WO2001014371A1 (en)	2001-03-01
HRP20020175B1 (hr)	2008-07-31
CA2376355C (en)	2009-10-27
US20030078265A1 (en)	2003-04-24
JP2003507476A (ja)	2003-02-25
IL148313A0 (en)	2002-09-12
HK1043594A1 (zh)	2002-09-20
RU2277094C2 (ru)	2006-05-27
CZ2002642A3 (cs)	2002-08-14
LT2002028A (en)	2002-09-25
EP1206467A1 (en)	2002-05-22
US20030069210A1 (en)	2003-04-10
US20030060452A1 (en)	2003-03-27
HUP0202450A2 (hu)	2002-11-28
DE60007329T2 (de)	2004-06-09
HK1051683A1 (en)	2003-08-15
NO323886B1 (no)	2007-07-16
HRP20020175A2 (en)	2005-10-31
LV12887B (en)	2003-01-20
US6887865B2 (en)	2005-05-03
NO20020925D0 (no)	2002-02-26
PT1206467E (pt)	2004-05-31
DE60007329D1 (de)	2004-01-29
NZ517411A (en)	2003-09-26
US6849739B2 (en)	2005-02-01
HUP0202450A3 (en)	2003-12-29
US20030073669A1 (en)	2003-04-17
BR0014144A (pt)	2002-05-21
EP1206467B1 (en)	2003-12-17
US20020183323A1 (en)	2002-12-05
IL148313A (en)	2008-04-13
PL353539A1 (en)	2003-12-01
US6432947B1 (en)	2002-08-13
RS50378B (sr)	2009-11-10
MXPA02002022A (es)	2002-10-31
SI20818A (sl)	2002-08-31
US6747031B2 (en)	2004-06-08
US6841674B2 (en)	2005-01-11
BG106440A (en)	2002-11-29
CN1206228C (zh)	2005-06-15
UA72930C2 (uk)	2005-05-16
KR20020062277A (ko)	2002-07-25
US20030004137A1 (en)	2003-01-02
US6846829B2 (en)	2005-01-25
AU769405B2 (en)	2004-01-29
US20030083332A1 (en)	2003-05-01
ZA200201485B (en)	2003-07-30

Publication	Publication Date	Title
LT4982B (lt)	2003-01-27	N-heterocikliniai dariniai kaip nos inhibitoriai
ES2292488T3 (es)	2008-03-16	Derivados de la urea, como agentes antiinflamatorios.
DE69612949T2 (de)	2001-09-20	Neue benzimidazolderivate mit cgmp-phosphodiesterase inhibierender wirkung
EA007062B1 (ru)	2006-06-30	Новые дигидроптеридиноны, способы их получения и их применение в качестве лекарственных средств
KR20090036573A (ko)	2009-04-14	신규한 피리딘 유사체
CA2453147A1 (en)	2003-01-23	Methods of treating cytokine mediated diseases
EA021025B1 (ru)	2015-03-31	Соединения, эффективные в качестве ингибиторов ксантиноксидазы, способ их получения и содержащая их фармацевтическая композиция
KR20090031605A (ko)	2009-03-26	신규한 피리딘 유사체
EP1567507B1 (en)	2006-06-14	1,2,3- triazole amide derivatives as cytokine inhibitors
US3169966A (en)	1965-02-16	Aminopyrazoles
CA2504213A1 (en)	2004-05-13	New beta-agonists, processes for preparing them and their use as pharmaceutical compositions
JPH1067753A (ja)	1998-03-10	新規ベンゾイミダゾール、ベンゾオキサゾール及びベンゾチアゾール化合物、その製造方法、並びにそれを含有する医薬組成物
EA010392B1 (ru)	2008-08-29	Производные имидазолов, способ их получения и их применение в качестве лекарственного средства
BRPI1007902B1 (pt)	2022-01-04	Compostos de fenilmidazol
JPH10513172A (ja)	1998-12-15	５−ｈｔ▲下１ｄ▼受容体アゴニストとしての置換１，４−ピペラジン−ヘテロアリール誘導体
JP2008501775A (ja)	2008-01-24	オキシトシン拮抗剤としての置換トリアゾール誘導体
BG100209A (bg)	1996-07-31	Пиролохинолинонови производни с позитивна инотропна и лузитропна активност
US5356922A (en)	1994-10-18	Imidazole compounds, processes for their preparation, pharmaceuticals based on these compounds and some intermediates
JPH0971564A (ja)	1997-03-18	ベンズアミドオキシム誘導体及びその医薬用途
JPS606689A (ja)	1985-01-14	トリスアゾロ〔２，３−ｃ〕〔１，３〕ベンゾジアゼピン類、その製法およびそれを含む医薬組成物
JPWO1994026737A1 (ja)	1995-08-03	イミダゾリルキノキサリンジオン誘導体及びその医薬組成物

Legal Events

Date	Code	Title	Description
2011-04-26	MM9A	Lapsed patents	Effective date: 20100824